Last reviewed · How we verify
NCT05440513: TUSK
A Study of Non-Vascular Renal Denervation Using the Verve Medical Phoenix ™ System
NA trial testing Renal Pelvic Denervation (bilateral) in Hypertension in 20 participants. Status unknown.
5 February 2022
Quick facts
| Lead sponsor | Verve Medical, Inc |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 25 January 2021 |
| Primary completion | 5 February 2022 |
| Estimated completion | 15 December 2022 |
| Sites | 2 locations across Georgia |
Drugs / interventions tested
- Renal Pelvic Denervation (bilateral)
Conditions studied
- Hypertension — all drugs for Hypertension →
- Uncontrolled Hypertension — all drugs for Uncontrolled Hypertension →
Sponsor
Verve Medical, Inc — full company profile →
Who can join
Adults 18 to 70, any sex, with Hypertension or Uncontrolled Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to assess the safety and effectiveness of a novel device for renal denervation to lower blood pressure in people with uncontrolled hypertension. Prior studies demonstrate the potential benefit of renal denervation in hypertension, though these studies primarily denervate the kidneys by passing catheters through the arteries in the groin into the renal arteries. The TUSK study utilizes the Phoenix system to perform denervation by advancing the device (a thin electrode) through the urinary tract into the kidneys where radiofrequency energy is briefly applied to denervate the kidneys.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension.
Hering D, Nikoleishvili D, Imedadze A, Dughashvili G, et al · · 2022 · cited 5× · PMID 36254733 · DOI 10.1161/hypertensionaha.122.20048
Verify or expand the search:
- PubMed search for NCT05440513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Verve Medical, Inc trials
Trials by the same sponsor.
- NCT07005050 — Renal Pelvic Denervation Pilot Trial · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05440513 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Verve Medical, Inc
- Last refreshed: 6 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05440513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing